European Journal of Pharmaceutics and Biopharmaceutics

www.elsevier.com/locate/eipb

Aims and Scope

The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for publication of novel and innovative research from the areas of Pharmaceutical Technology, Pharmaceutical Biotechnology and Biopharmaceutics.

Topics covered include: • Drug and pro-drug design, drug stability and drug development • Development, formulation and manufacturing of pharmaceuticals and biopharmaceuticals • Physical pharmacy, drug delivery systems, controlled release systems and drug targeting • Biopharmaceutics • Pharmaceutical analysis and pharmaceutical packaging • Quality control, GMP and regulatory aspects • Medical devices.

The following types of papers are considered by the Editors: Research Papers, Review Articles, Short Reviews (Expert Opinions) and Notes.

The Rules of 3

The Editors and Editorial board have developed the "Rules of 3". Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and reviewing at work:

- 1. The paper must report on recent advances in pharmaceutical technology, biopharmaceutics and pharmaceutical biotechnology of major importance.
- 2. A paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented.
- 3. The study described in the manuscript must represent a novel approach.

The rules are also used as guidelines for the peer review of manuscripts and are detailed on the journal homepage www.elsevier.com/locate/ejpb

Editor-in-Chief

Robert Gurny, School of Pharmaceutical Sciences, University of Geneva, 30, quai E.-Ansermet, CH-1211 Geneva 4, Switzerland

Wolfgang Friess, University of Munich, Department of Pharmaceutical Technology and Biopharmaceutics, Munich, Germany

Achim Göpferich, University of Regensburg, Institute of Pharmacy, Pharmaceutical Technology, Regensburg, Germany

Geoffrey Lee, University of Erlangen-Nürnberg, Institute for Pharmaceutical Technology, Erlangen, Germany

Claus-Michael Lehr, Helmholtz-Institute for Pharmaceutical Research and Saarland University, Saarbrücken, Germany

Jean-Christophe Leroux, ETH Galenische Pharmazie, Zurich, Switzerland

Karsten Mäder, Martin Luther University, Institute of Pharmacy, Pharmaceutical Technology, Halle/Saale, Germany

Michael Möller, University of Geneva, School of Pharmaceutical Sciences, Geneva, Switzerland

Thomas Rades, University of Otago, Dunedin, New Zealand

Michael Rathbone, International Medical University, Kuala Lumpur, Malaysia

Kishor Wasan, University of British Columbia, Division of Pharmaceutics and Biopharmaceutics, Vancouver, British Columbia, Canada

Sarra de Valence, University of Geneva, School of Pharmaceutical Sciences, Geneva, Switzerland

Editorial Advisory Board

- E. Allémann, University of Geneva, Switzerland
- J.M. Anderson, Case Western Reserve University, Cleveland, OH, USA
- S. Benita, Hebrew University of Jerusalem, Israel
- J.-P. Benoit, University of Angers, France
- A. Bernkop-Schnürch, University of Innsbruck, Austria
- M.J. Blanco-Prieto, University of Navarra, Pamplona, Spain
- R. Bodmeier, Freie University of Berlin, Germany
- J. Breitenbach, Abbott GbH & Co. KG, Ludwigshafen, Germany
- P. Breton, Université François Rabelais de Tours, France
- H. Bunjes, Technical University of Braunschweig, Germany
- M. Capelle, Therapeomic AG, Basel, Switzerland
- U. Conte, University of Pavia, Italy
- P. Couvreur, Université Paris Sud, France
- R. Daniels, University of Tübingen, Germany
- F. Delie-Salmon, University of Geneva, Switzerland
- B. Demeule, Genentech Inc., San Francisco, CA, USA
- T. Desai, University of California, San Francisco, CA, USA
- J.M. Devoisselle, University of Montpellier, France
- E. Doelker, University of Geneva, Switzerland
- J. Dressman, J.W. Goethe University, Frankfurt, Germany
- P. Esposito, SiTec PharmaBio, Barcelona, Spain
- B. Gander, ETH Zürich, Switzerland
- W.R. Gombotz, Omeros Corp., Seattle, WA, USA
- M. Gonzalez, P'Kinetics International, Pembroke Pines, FL, USA
- **R.H. Guy,** University of Bath, UK
- J. Hadgraft, University of London, UK
- J.A. Hubbell, EPFL, Lausanne, Switzerland
- H.E. Junginger, Marburg, Germany
- Y.N. Kalia, University of Geneva, Switzerland
- T. Kissel, Philipps University, Marburg, Germany

- P. Kleinebudde, H.-Heine University, Düsseldorf, Germany
- J. Knäblein, Schering AG, Berlin, Germany
- J. Kopecek, University of Utah, Salt Lake City, UT, USA
- J. Kreuter, J.W. Goethe University, Frankfurt, Germany
- N. Lange, University of Geneva, Switzerland
- V.H.L. Lee, The Chinese University of Hong Kong, Shatin, Hong Kong
- H. Lindner, Bayer Schering Pharma AG, Berlin, Germany
- H.L. Luessen, Tytonis BV, Alkmaar, The Netherlands
- E. Mathiowitz, Brown University, Providence, RI, USA
- R.H. Müller, Freie University of Berlin, Germany
- C. Müller-Goymann, University of Braunschweig, Germany
- T. Nagai, The Nagai Foundation, Tokyo, Japan
- R.H.H. Neubert, Martin Luther University, Halle, Germany
- A.F. Öner, Hacettepe University, Ankara, Turkey
- G.M. Pauletti, University of Cincinnati, OH, USA
- N.A. Peppas, University of Texas, Austin, TX, USA
- V. Préat, Université Catholique de Louvain, Belgium
- K. Roy, University of Texas at Austin, TX, USA
- S. Rudaz, University of Geneva, Switzerland
- C. Rudolph, Ludwig Maximilians University, Munich, Germany
- L. Scapozza, University of Geneva, Switzerland
- R. Schubert, Albert Ludwigs University, Freiburg, Germany
- J. Siepmann, University of Lille, France
- K.J. Tojo, Kyushu Institute of Technology, Lizuka, Fukuoka, Japan
- V. Torchilin, Northeastern University, Boston, MA, USA
- C. Valenta, University of Vienna, Austria
- W. Weitschies, University of Greifswald, Germany
- C.G. Wilson, University of Strathclyde, Glasgow, UK G. Winter, Ludwig Maximilian University, Munich, Germany
- A. Zimmer, University of Graz, Austria